Insider Selling: Exagen (NASDAQ:XGN) Major Shareholder Sells $69,167.10 in Stock

Exagen Inc. (NASDAQ:XGN) major shareholder Jorey Chernett sold 11,265 shares of the stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $6.14, for a total transaction of $69,167.10. Following the completion of the transaction, the insider owned 2,610,040 shares in the company, valued at $16,025,645.60. This trade represents a 0.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Tuesday, November 10th, Jorey Chernett bought 7,085 shares of Exagen stock. The shares were acquired at an average cost of $5.26 per share, with a total value of $37,267.10.
• On Monday, November 9th, Jorey Chernett purchased 8,500 shares of Exagen stock. The shares were acquired at an average price of $6.35 per share, for a total transaction of $53,975.00.
• On Monday, October 19th, Jorey Chernett acquired 14,000 shares of Exagen stock. The shares were acquired at an average cost of $7.46 per share, with a total value of $104,440.00.

Exagen Price Performance

NASDAQ XGN traded down $1.84 on Tuesday, hitting $5.26. 2,191,440 shares of the company traded hands, compared to its average volume of 415,796. The company has a debt-to-equity ratio of 1.96, a current ratio of 3.18 and a quick ratio of 3.18. The business’s 50 day moving average price is $7.88 and its 200-day moving average price is $5.13. Exagen Inc. has a 52-week low of $2.59 and a 52-week high of $9.73.

Exagen (NASDAQ:XGN) last released its earnings results on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Exagen had a negative return on equity of 104.46% and a negative net margin of 26.61%. The firm had revenue of $18.42 million for the quarter, compared to the consensus estimate of $18.34 million. On average, equities analysts expect that Exagen Inc. will post -0.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on XGN. TD Cowen raised their price objective on shares of Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. B. Riley Financial assumed coverage on shares of Exagen in a report on Friday, September 11th. They issued a “buy” rating and a $12.00 target price for the company. BTIG Research increased their price target on Exagen from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Exagen in a report on Wednesday, November 4th. Finally, Canaccord Genuity Group raised their price target on Exagen from $9.00 to $11.00 and gave the company a “buy” rating in a report on Monday, October 19th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Exagen currently has an average rating of “Moderate Buy” and an average target price of $10.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XGN. FourWorld Capital Management LLC grew its holdings in Exagen by 61.2% during the 1st quarter. FourWorld Capital Management LLC now owns 439,950 shares of the company’s stock valued at $1,320,000 after buying an additional 166,950 shares in the last quarter. Flputnam Investment Management Co. purchased a new position in shares of Exagen in the second quarter worth $1,343,000. Sei Investments Co. lifted its holdings in shares of Exagen by 107.0% in the first quarter. Sei Investments Co. now owns 244,240 shares of the company’s stock worth $733,000 after buying an additional 126,235 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Exagen in the second quarter worth $998,000. Finally, Renaissance Technologies LLC boosted its position in shares of Exagen by 47.3% during the first quarter. Renaissance Technologies LLC now owns 203,272 shares of the company’s stock worth $610,000 after acquiring an additional 65,272 shares during the last quarter. 75.25% of the stock is currently owned by institutional investors.

More Exagen News

Here are the key news stories impacting Exagen this week:

• Positive Sentiment: Third-quarter revenue rose 7% year over year to $18.4 million, slightly above analysts’ estimates. For the first nine months, revenue grew 11%, net loss narrowed 12%, and adjusted EBITDA loss improved more than 30%. Exagen third-quarter results
• Positive Sentiment: Major shareholder Jorey Chernett’s reported purchases on Nov. 9 and 10 exceeded his Nov. 6 sale by 4,320 shares overall, a modest signal of confidence. Exagen also reiterated its 2026 revenue outlook of $72 million to $75 million and expects to launch its myositis offering in early 2027.
• Neutral Sentiment: Revenue guidance includes the analyst consensus estimate of $73.9 million, making the reaffirmation broadly in line with expectations rather than a clear forecast upgrade.
• Negative Sentiment: Exagen reported a loss of $0.25 per share, wider than estimates of about $0.18–$0.19. Operating expenses increased, widening the quarterly operating loss to $4.4 million from $3.1 million a year earlier; quarterly adjusted EBITDA loss also edged wider. Cash was $28.1 million, down from $35.7 million a year earlier. These results raise concerns about near-term profitability and cash use despite sales growth.

About Exagen

Exagen Inc. is a commercial-stage diagnostic company focused on improving the diagnosis and management of autoimmune and rheumatic diseases. The company develops and commercializes blood tests that help physicians identify autoimmune disease, distinguish among related conditions and monitor disease activity over time. Its principal product family is AVISE, which includes the AVISE CTD and AVISE Lupus tests, as well as monitoring and specialty tests used in the evaluation of systemic lupus erythematosus and other connective-tissue diseases.